Latest Conference Coverage

Evaluating Intra-Arterial Tenecteplase for Stroke: Insights From the ANGEL-TNK Trial: Xiaochuan Huo, MD, PhD

The director of the neurological disease center at Beijing Anzhen Hospital talked about assessing the potential benefits and safety of intra-arterial tenecteplase in highly selected poststroke patients. [WATCH TIME: 6 minutes]

Endovascular Thrombectomy Provides No Additional Benefit in Medium Vessel Occlusion Stroke, ESCAPE-MeVO Results Show

In addition to failing to separate itself on the primary end point, EVT + best medical care was associated with higher rates of serious adverse events (33.9% vs 25.7%) and mortality (13.3% vs 8.4%) compared to best medical care alone.

Using Practical Training to Enhance Movement Disorder Care: Clarisse Goas MSN, APRN-CNP

Mild Electrical Brain Stimulation Fails to Boost Poststroke Recovery in Phase 2 Study

In a recently presented study at ISC 2025, poststroke patients reported no additional benefit from using transcranial direct current stimulation as a potential intervention for recovery.

Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MSc

The chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]

What to Expect at MDA’s 2025 Clinical and Scientific Conference: Barry J. Byrne, MD, PhD

The chief medical advisor at the Muscular Dystrophy Association shared key highlights of what attendees can expect at the 2025 MDA Clinical and Scientific Conference. [WATCH TIME: 4 minutes]

Insights From the Pediatric Epilepsy Research Consortium on Advancing Genetic Testing

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

Pediatric AES Insights: Addressing Health Disparities and Advancing Neonatal Epilepsy Care

Pediatric epilepsy specialists Adam Numis, MD, and Laura Kirkpatrick, MD, highlighted efforts to standardize data collection for pediatric epilepsy health equity and improve neonatal epilepsy outcomes.

Insights From the Child Neurology Foundation: Enhancing Pediatric Epilepsy Care Through Holistic Collaboration

Jessica Nickrand, PhD, and Allyson Eyermann from the Child Neurology Foundation emphasized the importance of multidisciplinary collaboration for children with epilepsy and their families.

Implications of New Multiple Sclerosis Criteria on Overlapping Autoimmune Conditions: Joseph Kuchling, MD

At ECTRIMS 2024, the postdoctoral research assistant at Charité University Berlin discussed how the updated diagnostic criteria aim to address gaps in diagnosing and treating overlapping autoimmune conditions. [WATCH TIME: 4 minutes]

Improving MS Management Through Early Intervention and Precision Medicine: Emilio Portaccio, MD

The professor of neurology at University of Florence talked about how early intervention, broader assessment tools, and personalized approaches are essential for effectively managing multiple sclerosis. [WATCH TIME: 4 minutes]

NeuroVoices: Jacqueline A. French, MD, on Leveraging Neurostimulators to Advance Epilepsy Drug Development

The professor of neurology at NYU Grossman School of Medicine talked about using responsive neurostimulators to seek shortened drug evaluation timelines and enhance epilepsy treatment.

Bridging Clinical Signs and Biological Evidence to Transform MS Diagnosis: Marcello Moccia, MD, PhD

At ECTRIMS 2024, the assistant professor at the University of Naples the latest multiple sclerosis diagnostic criteria, which emphasized a shift toward biologically based diagnoses. [WATCH TIME: 4 minutes]

Navigating the Decision to Treat Multiple Sclerosis Early Versus Later: Mikael Cohen, MD

At the 2024 ECTRIMS Congress, the neurologist at the University Hospital Center of Nice talked about how the decision to treat patients at risk of MS is highly individualized. [WATCH TIME: 3 minutes]

Improving MS Diagnosis Through Biology and Early Detection: Wallace Brownlee, MBChB, PhD, FRACP

At ECTRIMS 2024, the consultant neurologist at Queen's Square MS Center in London talked about the evolving McDonald criteria to define multiple sclerosis biologically. [WATCH TIME: 5 minutes]

The Philosophy and Future of the DAAE Score in Multiple Sclerosis Care: Tom Fuchs, MD, PhD

At ECTRIMS 2024, the postdoctoral researcher at Amsterdam University Medical Center talked about an evolving tool developed to predict disease progression in multiple sclerosis. [WATCH TIME: 7 minutes]

Optimizing MS Treatment With Timely Interventions and Individualized Care: Valentin Krüger, MD

The neurology resident at the University Hospital Frankfurt in Germany talked about the importance of initiating treatment early for patients with multiple sclerosis to improve long-term outcomes. [WATCH TIME: 6 minutes]

Rethinking Treatment Strategies in NMOSD Based on Safety Failures and Emerging Therapies: Shamik Bhattacharyya, MD

The associate professor of neurology at Harvard Medical School talked about reconsidering therapy switches for NMOSD, incorporating safety failures like recurrent infections, and prioritizing real-world studies to validate findings. [WATCH TIME: 5 minutes]

Clinical Program and Next Steps for Zorevunersen as Potential Disease-Modifying Treatment for Dravet: Barry Ticho, MD, PhD

The chief medical officer at Stoke Therapeutics discussed recent developments for zorevunersen, including the significance of breakthrough therapy designation and its plan for a phase 3 trial. [WATCH TIME: 5 minutes]

Optimizing Epilepsy Treatments: Stiripentol’s Role in Dravet Syndrome

James Wheless, MD, FAAP, FAAN, FAES, Le Bonheur Chair in Pediatric Neurology at the University of Tennessee Health Science Center, shared insights on his presentation from AES 2024, focusing on stiripentol, an FDA-approved treatment for Dravet syndrome.

Advancing Understanding of the Preclinical Phase of Multiple Sclerosis: Christina J. Azevedo, MD

At the 2024 ECTRIMS Congress, the associate professor of clinical neurology at Keck School of Medicine of USC talked about recent research that highlights the preclinical phase of multiple sclerosis. [WATCH TIME: 9 minutes]

Stoke Announces Phase 3 EMPEROR Registrational Study for Zorevunersen in Dravet Syndrome

The global Phase 3 trial aims to enroll ~150 patients with Dravet syndrome who have SCN1A variants, assessing zorevunersen's impact on seizure frequency, behavior, cognition, and safety over 60 weeks, with results expected by 2027.

NeuroVoices: Fred Lublin, MD, on Shifting From Phenotypes to Spectrum-Based Perspectives to Advance Multiple Sclerosis Care

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about how modern advances research have helped transition the understanding of multiple sclerosis from fixed phenotypes to a dynamic spectrum.

Raising Awareness and Advancing Management for Developmental Epileptic Encephalopathy With Spike Wave Activation

Lekha Rao, MD, an epileptologist at UCLA Health, discussed the challenges in diagnosing D/EE-SWAS, the importance of early EEG, and the need for greater awareness around this rare and complex epileptic condition.

Overlapping Diagnoses and the Advancement of MS Detection in NMDARE: Joseph Kuchling, MD

The postdoctoral research assistant at Charité University Berlin discussed advances in diagnostic criteria and 7-Tesla MRI imaging, highlighting a previously overlooked overlap between anti-N-methyl-D-aspartate receptor encephalitis and multiple sclerosis. [WATCH TIME: 5 minutes]

Reducing the Burden: Proactive Care Strategies for Lennox-Gastaut Syndrome

Babitha Haridas, MD, MBBS, a pediatric epileptologist at Johns Hopkins Medicine, discussed the complexities with managing status epilepticus in Lennox-Gastaut syndrome, focusing on the importance of identifying triggers early in their condition.

Evolving MS Diagnostics From Categorical Classifications to Biological Phenotyping: Fred Lublin, MD

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai talked about the shift in multiple sclerosis diagnostics from rigid classification systems to a dynamic, spectrum-based approach focused on biological phenotyping. [WATCH TIME: 5 minutes]

Defining Progression Independent of Relapsing Activity and Insights into Early Multiple Sclerosis Progression: Emilio Portaccio, MD

The professor of neurology at University of Florence talked about a study presented at ECTRIMS 2024 that validated definitions of progression independent of relapse activity in early relapsing MS. [WATCH TIME: 5 minutes]

Improving Access and Reducing Latency in Genetic Testing for Epilepsy: Julie Ziobro, MD, PhD; John Schreiber, MD

A duo of experts discussed the importance of addressing barriers such as provider comfort, access to genetic counselors, and insurance coverage to reduce diagnostic latency and standardize genetic testing for epilepsy. [WATCH TIME: 5 minutes]

Studying Nerve Cell Therapy NRTX-1001 to Treat Mesial Temporal Lobe Epilepsy: Jonathan Parker, MD, PhD

The assistant professor of neurosurgery and neuroscience at Mayo Clinic Arizona discussed an ongoing early-stage study assessing the therapeutic potential of NRTX-1001 nerve cell therapy in drug-resistant unilateral mesial temporal lobe epilepsy. [WATCH TIME: 5 minutes]